Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	8/21/2006 1:32:36 PM
	Read Replies (1) of 3044

Millennium Pharmaceuticals "neutral" Monday, August 21, 2006 3:46:28 AM ET Robert W. Baird NEW YORK, August 21 (newratings.com) - Analysts at Robert W Baird reiterate their "neutral" rating on Millennium Pharmaceuticals Inc (MLNM.NAS). The target price is set to $11. In a research note published this morning, the analysts mention that the recently undertaken hematologist survey suggests that Velcade continues to maintain its market share in multiple myeloma (MM) and is gaining physician preference for the treatment of NHL. The analysts expect Velcade sales to exceed the estimates for FY06.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next